Engle et al. found that CA19-9 expression resulted in hyperactivation of epidermal growth factor receptor (EGFR) signaling, which interacts with the KrasG12D oncogene to produce aggressive pancreatic cancer cells, indicating that CA19-9 may be a useful therapeutic target.[29] We can infer that CA19-9 is related to the malignant degree of pancreatic cancer, possibly through EGFR signaling and its synergistic effects with KrasG12D. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.